New findings by UT Southwestern researchers suggest that a drug already used to treat autoimmune disorders might also help slow the destruction of insulin-producing cells in patients recently diagnosed with insulin-dependent (type 1) diabetes. In type 1 diabetes, formerly known as juvenile diabetes, cells in the pancreas called beta cells, which produce insulin, are destroyed by an autoimmune process…

Original post:
FDA Approved Drug May Slow Beta Cell Destruction In Type 1 Diabetes Patients

Related posts:

1. FDA Approved Leukemia Drug Shows Promising Activity In Ovarian Cancer CellsThe drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and...
2. FDA Approves New Drug For Rare Cancer Cutaneous T-Cell LymphomaThe US Food and Drug Administration (FDA) has approved a new drug for treating patients with the rare white blood cell cancer Cutaneous T-cell Lymphoma (CTCL); the drug Istodax (romidepsin)...
3. What Are The Different Type Of Diabetes?Diabetes mellitus mainly comes when pancreas does not produce in sufficient amounts or any of hormone insulin or when insulin is generated that does not perform out efficiently....
4. ‘Rational Drug Design’ Identifies Fragments Of FDA-Approved Drugs Relevant To Emerging VirusesA massive, data-crunching computer search program that matches fragments of potential drug molecules to the known shapes of viral surface proteins has identified several FDA-approved drugs that could be the...
5. FDA Approves Gloucester Pharmaceuticals’ ISTODAX(R) For Patients With Cutaneous T-cell LymphomaGloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least...
6. FDA Approves Gloucester Pharmaceuticals’ ISTODAX(R) For Patients With Cutaneous T-cell LymphomaGloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least...
7. New Type 2 Diabetes And Obesity Treatment Approved – EndoBarrier Receives European CE MarkGI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier(TM), a non-surgical therapy...
8. Islet Cell Transplantation In ScotlandThe Scottish National Blood Transfusion Service has opened a new laboratory in Edinburgh to offer around 12 people a year islet cell transplant therapy. Islet cell transplant therapy is a...
9. Echo Therapeutics Announces Positive Results Of A Clinical Study Testing Symphony(TM) TCGM System In Patients With Type 1 And Type 2 DiabetesEcho Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System...
10. Two Thirds Of Brits Do Not Know The Difference Between Type 1 And Type 2 DiabetesNew research out today reveals that less than a third of UK residents (30 per cent) know of type 1 diabetes with a further 59 per cent confusing the autoimmune...
11. Cardiovascular Risk In Youth With Type 1 Diabetes Linked Primarily To Insulin ResistanceAccording to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), youth with type 1 diabetes have now been found to have...
12. Advanced Cell Technology Files IND With FDA For First Human Clinical Trial Using Embryonic Stem Cells To Treat Eye DiseaseAdvanced Cell Technology, Inc. (OTCBB:ACTC) announced that it filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study...
13. Genetics and Lifestyle Risk Factors for Type 2 DiabetesType 2 Diabetes Causes - Genetics & Lifestyle Risk Factors...
14. Pioneering Discoveries About The Development Of CellsHow does the developing pancreas in an embryo 'know' which cells are to produce insulin and which cells are to have other assignments? Researchers need to understand this if they...
15. FDA Approves New Drug For Pain That Persists After ShinglesThe US Food and Drug Administration (FDA) announced yesterday that it has approved Qutenza (capsaicin) 8% patch for the treatment of post-herpetic neuralgia (PHN), an often excruciating pain that can...